Colorado Blood Cancer Institute - Academic Profile

Publications

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke , Armin Ghobadi , Caron A. Jacobson +28 more

2018 The Lancet Oncology 2108 citations

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang , Javier Muñoz , André Goy +22 more

KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that...

2020 New England Journal of Medicine 1666 citations

Affiliated Researchers

Peter A. McSweeney

Colorado Blood Cancer Institute

Institution Info

Type: healthcare
Country: US
Publications: 2
Citations: 3,774

External Links

Identifiers

ROR: https://ror.org/040pncp85